Combination therapy of therapeutic antibody and vaccine or entecavir in HBV carrier mice

Ruoyao Qi; Jiali Cao; Yangtao Wu; Xing Lei; Jinhang He; Liang Zhang; Rao Fu; Feng Chen; Yingbin Wang; Tianying Zhang; Ningshao Xia; Quan Yuan

doi:10.3389/fmicb.2023.1173061

Combination therapy of therapeutic antibody and vaccine or entecavir in HBV carrier mice

Front Microbiol. 2023 May 5:14:1173061. doi: 10.3389/fmicb.2023.1173061. eCollection 2023.

Authors

Ruoyao Qi^{1

2}, Jiali Cao³, Yangtao Wu^{1

2}, Xing Lei^{1

2}, Jinhang He^{1

2}, Liang Zhang^{1

2}, Rao Fu^{1

2}, Feng Chen^{1

2}, Yingbin Wang^{1

2}, Tianying Zhang^{1

2}, Ningshao Xia^{1

2}, Quan Yuan¹

Affiliations

¹ State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian, China.
² National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, Fujian, China.
³ Department of Clinical Laboratory, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China.

Abstract

Chronic infection with the hepatitis B virus (HBV) is a leading causes of liver cirrhosis and hepatocellular carcinoma. However, managing HBV treatments is challenging due to the lack of effective monotherapy. Here, we present two combination approaches, both of which aim to target and enhance the clearance of HBsAg and HBV-DNA. The first approach involves the use of antibodies to continuously suppress HBsAg, followed by the administration of a therapeutic vaccine in a sequential manner. This approach results in better therapeutic outcomes compared to the use of these treatments individually. The second approach involves combining antibodies with ETV, which effectively overcomes the limitations of ETV in suppressing HBsAg. Thus, the combination of therapeutic antibodies, therapeutic vaccines, and other existing drugs is a promising strategy for the development of novel strategies to treat hepatitis B.

Keywords: HBV; combination (combined) therapy; nucleotid analogs; therapeutic antibodies; therapeutic vaccine.